Novel triterpene derivatives, preparation thereof and use thereof

Details for Australian Patent Application No. 2004276307 (hide)

Owner Panacos Pharmaceuticals, Inc.

Inventors Ashton, Mark; Robinson, Gary N.; Wild, Carl T.; Thomas, Russell

Agent Houlihan2

Pub. Number AU-A-2004276307

PCT Pub. Number WO2005/030790

Priority 60/505,899 26.09.03 US; 60/559,358 05.04.04 US

Filing date 27 September 2004

Wipo publication date 7 April 2005

International Classifications

C07J 1/00 (2006.01) Normal steroids, i.e. cyclopenta[a]hydrophenanthrenes, containing carbon, hydrogen, halogen, or oxygen

A61K 31/225 (2006.01)

A61K 31/56 (2006.01) - Compounds containing cyclopenta[a]hydrophenanthrene ring systems

C07C 69/608 (2006.01) Esters of carboxylic acids

C07J 53/00 (2006.01) Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by condensation with carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms

Event Publications

30 March 2006 PCT application entered the National Phase

  PCT publication WO2005/030790 Priority application(s): WO2005/030790

4 September 2008 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004276309-Apparatus and method for making preforms in mold

2004276306-Altering a B cell pathology using selfderived antigens in conjunction with specific-binding cytoreductive agent